DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Wellbutrin (Bupropion Hydrochloride) - Summary

 

-- advertisement --

Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of WELLBUTRIN or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. WELLBUTRIN is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for Patients, and PRECAUTIONS: Pediatric Use.)

 

WELLBUTRIN SUMMARY

WELLBUTRIN®
(bupropion hydrochloride)
Tablets

WELLBUTRIN (bupropion hydrochloride), an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines. It is designated as (±)-1-(3-chlorophenyl)-2-[(1,1-dimethylethyl)amino]-1-propanone hydrochloride.

WELLBUTRIN is indicated for the treatment of depression. A physician considering WELLBUTRIN for the management of a patient's first episode of depression should be aware that the drug may cause generalized seizures in a dose-dependent manner with an approximate incidence of 0.4% (4/1,000). This incidence of seizures may exceed that of other marketed antidepressants by as much as 4-fold. This relative risk is only an approximate estimate because no direct comparative studies have been conducted (see WARNINGS).

The efficacy of WELLBUTRIN has been established in 3 placebo-controlled trials, including 2 of approximately 3 weeks' duration in depressed inpatients and one of approximately 6 weeks' duration in depressed outpatients. The depressive disorder of the patients studied corresponds most closely to the Major Depression category of the APA Diagnostic and Statistical Manual III.

Major Depression implies a prominent and relatively persistent depressed or dysphoric mood that usually interferes with daily functioning (nearly every day for at least 2 weeks); it should include at least 4 of the following 8 symptoms: change in appetite, change in sleep, psychomotor agitation or retardation, loss of interest in usual activities or decrease in sexual drive, increased fatigability, feelings of guilt or worthlessness, slowed thinking or impaired concentration, and suicidal ideation or attempts.

Effectiveness of WELLBUTRIN in long-term use, that is, for more than 6 weeks, has not been systematically evaluated in controlled trials. Therefore, the physician who elects to use WELLBUTRIN for extended periods should periodically reevaluate the long-term usefulness of the drug for the individual patient.

WELLBUTRIN NEWS HIGHLIGHTS

Media Articles Related to Wellbutrin (Bupropion)

Nicotine Patch May Be More Helpful Than Bupropion for Adolescent Smoking Cessation
Source: Medscape Primary Care Headlines [2004.08.19]

Empatic™ Shows Long-Term Weight Loss, Improved Quality Of Life Contrave(R) Reduces Rate Of Metabolic Syndrome By Half
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2008.10.07]

Orexigen(R) Therapeutics Presents Data On Its Proprietary Formulation Of Naltrexone Sustained Release (SR) Used In Contrave(R)
Source: Obesity / Weight Loss / Fitness News From Medical News Today [2008.10.07]

more>>

Published Studies Related to Wellbutrin (Bupropion)

Randomized, placebo-controlled trial of bupropion for the treatment of methamphetamine dependence. [2008.08.01]

Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. [2008.07.17]

A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. [2008.06.01]

A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertension. [2008.06]

Toward Personalized Therapy for Smoking Cessation: A Randomized Placebo-controlled Trial of Bupropion. [2008.04.02]

more>>

Clinical Trials Related to Wellbutrin (Bupropion)

Wellbutrin XL, Major Depressive Disorder and Breast Cancer [Completed]

The Effects of Acute Administration of Bupropion on Neural Substrates Underlying Hedonic Capacity [Completed]

Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation [Completed]

Chantix & Bupropion for Smoking Cessation [Active, not recruiting]

Wellbutrin XL for Dysthymic Disorder [Completed]

more>>

Page last updated: 2008-10-07

-- advertisement -- The American Red Cross

We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2008